A Randomized Trial of Postoperative Adjuvant Therapy in Patients with Completely Resected Stage II or IIIa Non–Small-Cell Lung Cancer

2000450 citationsJournal Articlebronze Open Access

Authors

Steven M. Keller · Mount Sinai Beth Israel

Sudeshna Adak · North Central Cancer Treatment Group

Henry Wagner · Moffitt Cancer Center

Arnold Herskovic · North Central Cancer Treatment Group

Ritsuko Komaki · North Central Cancer Treatment Group

Burke J. Brooks · RTOG Foundation

Michael C. Perry

Abstract

As compared with radiotherapy alone, adjuvant radiotherapy and chemotherapy with cisplatin and etoposide does not decrease the risk of intrathoracic recurrence or prolong survival in patients with completely resected stage II or IIIa non-small-cell lung cancer.

Topics & Keywords

Lung Cancer Diagnosis and Treatment Lung Cancer Treatments and Mutations Head and Neck Cancer Studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 343, Issue 17, pp. 1217-1222

DOI: 10.1056/nejm200010263431703

Field-Weighted Citation Impact: 26.16